SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Sage Therapeutics, Inc. – SAGE NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Anthos Therapeutics Announces Appointment of Bill Meury as CEO CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a…
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported…
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing…
Agile Therapeutics Announces Delisting from Nasdaq PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”),…
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company…
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical…
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…